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Abstract
Background: Gastric cancer (GC) is characterized by the excessive deposition of extracellular matrix, which is
thought to contribute to this tumor’s malignant behavior. Epithelial-mesenchymal transition (EMT) is regarded as
a crucial contributing factor to cancer progression. Galectin-1 (Gal-1), a β-galactoside-binding protein abundantly
expressed in activated cancer-associated fibroblasts (CAFs), has been reported to be involved in GC progression and
metastasis by binding to β1 integrin, which, in turn, can bind to matrix proteins and activate intracellular cascades
that mediate EMT. Increasing evidence suggests that abnormal activation of the hedgehog (Hh) signaling pathway
enhances GC cell migration and invasion. The purpose of our study is to explore the role of Gal-1 in the GC
progression and metastasis as well as the regulatory mechanism.
Methods: We hypothesized that Gal-1 binding to β1 integrin would lead to paracrine signaling between CAFs and
GC cells, mediating EMT by upregulating Gli1. Invasion and metastasis effects of the Gal-1 and Gli1 were evaluated
using wound healing and invasion assay following transfection with mimics. Additionally, to facilitate the
delineation of the role of the Hh signaling in GC, we monitored the expression level of associated proteins. We
also evaluated the effects of β1 integrin on these processes. Furthermore, Gal-1 and Gli1 expression in GC patient
samples were examined by immunohistochemistry and western blot to determine the correlation between their
expression and clinicopathologic characteristics. The Kaplan-Meier method and Cox proportional hazards model
were used to analyze the relationship of expression with clinical outcomes.
Results: Gal-1 was found to induce EMT, GC cell migration and invasion. Further data showed that Gal-1 up-
regulated Gli1 expression. β1 integrin was responsible for Gal-1-induced Gli1 expression and EMT. In clinical GC
tissue, it confirmed a positive relationship between Gal-1 and Gli1 expression. Importantly, their high expression is
correlated to poor prognosis.
Conclusion: Gal-1 from CAFs binds to a carbohydrate structure in β1 integrin and plays an important role in the
development of GC by inducing GC metastasis and EMT through targeting Gli1. This study highlights the
potential therapeutic value of Gal-1 for suppression of GC metastasis.
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Background
The development of gastric cancer (GC) is a complex,
multi-step process associated with an enormous number
of genetic alterations, upregulation of cancer-causing
genes, downregulation of tumor-suppressor genes, and
the acquisition of metastatic ability [1]. A high proportion
of deaths related to GC is caused by tumor metastasis,
postoperative recurrence, and delayed detection of ad-
vanced stage disease [2, 3]. During the process of metasta-
sis and invasion, tumor cells are able to induce a series of
changes characterized by diffusible growth factors and
cytokines, components of the extracellular matrix, fibro-
blasts, and myofibroblasts (also called cancer-associated
fibroblasts [CAFs]), comprising the tumor microenvir-
onment [4]. Evidence from clinical and epidemiological
studies has shown a strong association between CAFs
and poor prognosis in several types of cancer, including
GC [5, 6].
Metastatic progression, the spread of primary tumors
to distant organs, is a complex, multistep physiological
process [1]. A large number of studies have shown that
epithelial-mesenchymal transition (EMT) plays a critical
role in cancer cell invasion and metastasis, and leads to
downregulation of epithelial-associated markers such as
E-cadherin and upregulation of mesenchymal markers
such as vimentin [7]. As a result of EMT, tumor cells
acquire metastatic and invasive properties, exhibit char-
acteristics that resemble embryonic mesenchymal cells,
and have an enhanced ability to penetrate the sur-
rounding stroma to initiate the formation of new neo-
plastic foci [8].
Galectin-1 (Gal-1), the first protein of the galectin
family of carbohydrate-binding lectins, can act as a bio-
logical modifier in tumor growth and metastasis [9].
Our previous work demonstrated that Gal-1, a kind of
secretory protein, is overexpressed in CAFs [6], pro-
moting gastric tumorigenesis and angiogenesis [6, 10].
Recently, Bacigalupo et al. demonstrated that Gal-1
could induce EMT in hepatocellular carcinoma [11].
However, investigations of Gal-1 in GC are scarce. The ex-
pression pattern of Gal-1 in human GC tissues and cell
lines, its biological roles, and potential mechanisms con-
tributing to GC progression still need to be addressed.
Major signaling pathways involved in EMT include
the TGF-β, Wnt, Notch, and Hedgehog (Hh) pathways
[12]. In GC, tumorigenicity and EMT are regulated
through activation of glioma-associated oncogene 1 (Gli1),
a key member of the Hh signaling pathway [13–15]. Hh
signaling during embryogenesis promotes tissue growth,
tissue patterning, vascularization, and differentiation, all of
which are processes that tumor cells employ in order to
support tumor growth and facilitate metastasis [11]. The
key signaling molecules in the Hh complex network are
considered to be oncogenes, including sonic hedgehog
(SHH), smoothened (SMO) and Gli1 [16]. Aberrant acti-
vation of Hh/Gli1 has been recognized as a key mediator
of metastasis via EMT [17]. Furthermore, dysregulation of
Gli1, a key transcription factor in the Hh pathway, has also
been shown to affect EMT in cancer cell lines and lymph-
atic metastasis [16], including GC [18, 19].
The β1 integrin chain (β1 integrin), a member of the
integrin family of cellular surface adhesion receptors,
contains the lactosamine sequence in its extracellular
domain [20]. Overexpression of β1 integrin contributes
to a loss of cell adhesion. Gal-1 exerts its biological ef-
fects by binding to lactosamine sequences of β1 integ-
rin [20, 21]. He et al. have shown that Gal-1 expressed
in CAFs promotes the invasiveness of GC cells by dir-
ect binding to β1 integrin on the cell surface [22].
Herein, we examined the ability of Gal-1 binding to
the carbohydrate structure of β1 integrin to induce EMT
via the Hh pathway in GC cell lines.
Methods
Patient selection and tissue preparation
From January 2012 to August 2012, 111 patients with GC
were treated at the Department of Gastrointestinal Sur-
gery, Clinical Medical College of Yangzhou University
(Subei People’s Hospital of Jiangsu Province). The clinico-
pathological features of these patients are shown in
Table 1 and Additional file 1. All patients underwent
radical resection; no patients received either chemo-
therapy or radiotherapy before surgery. This study
followed the tenets of the Declaration of Helsinki, and
informed written consent was obtained from all pa-
tients and controls after clinicians explained the nature
and possible consequences of the study. The study
protocol was approved by the Medical Ethics Commit-
tee of First Clinic Medical School of Yangzhou Univer-
sity (YZU-EC-JS2352).
Antibodies
Anti-galectin-1 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-β1-integrin subunit antibody (Cell
Signaling Technology, Danvers, MA, USA), anti-SMO
antibody (Abcam, Cambridge, UK), anti-Gli1 antibody
(Abcam), anti-SHH antibody (Abcam), anti-E-Cadherin
antibody (Cell Signaling Technology, Danvers, MA, USA),
anti-Vimentin (Cell Signaling Technology), anti-Snail
(Cell Signaling Technology), anti-MMP9 (Cell Signaling
Technology), anti-β-actin antibody (Beyotime, Jiangsu,
China), HRP-conjugated goat anti-mouse IgG and HRP-
conjugated goat anti-rabbit IgG (Santa Cruz Biotechnol-
ogy) were used in this study.
Immunohistochemistry
Immunohistochemical staining of human paraffin-
embedded GC and normal tissue sections was carried
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out as previously described with minor modifications
[10]. Briefly, after antigen retrieval, slides were incu-
bated with primary antibodies against galectin-1 or
Gli1 overnight at 4 °C, followed by incubation with
biotin-conjugated secondary antibodies, then horserad-
ish peroxidase-conjugated streptavidin. The sections
were stained with DAB and counterstained with
hematoxylin. Negative controls were treated identically,
though the primary antibodies were omitted. Staining
density was scored using standard methods, as de-
scribed previously [10]: negative staining was defined as
negative (no visible staining) or weak staining (light
brown staining in < 20 % of tumor cells); positive stain-
ing as moderate or strong staining (brown or dark
brown staining in > 20 % of tumor cells).
Cell preparations
CAFs were isolated from human gastric carcinoma
tissue, while primary human normal gastric fibroblasts
(NGFs) were obtained from a non-cancerous region at
least 5 cm from the outer tumor margin in the same pa-
tient. The primary cells were cultured as our previously
described [6]. The human GC lines MGC803, AGS,
MNK-45, MKN-28, SGC7901 and BGC-823 were pur-
chased from the Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). MGC-803 and
AGS cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Hyclone, Logan, Utah, USA)
supplemented with 10 % FBS and the other cell lines in-
cluding NGFs and CAFs were cultured in Roswell Park
Memorial Institute (RPMI) 1640 medium (Hyclone) con-
taining 10 % FBS. All cells were maintained at 37 °C in a
humidified atmosphere containing 5 % CO2. Before ex-
periments, GC cells in log phase growth in six-well
plates were cultured in media containing only 1 % FBS
for 24 h.
Lentiviral production and transduction
Human LGALS1 (GenBank accession numberNM_002305)
was inserted into the GV248 and GV358 lentiviral vectors
(Genechem, Shanghai, China) to silence and upregulate
the expression of Gal-1, respectively. The three shRNA se-
quences were as follows: Gal-1 sh1 (5′-CCGGCACCAT
CGTGTGCAACAGCAACTCGAGTTGCTGTTGCACA
CGATGGTGTTTTTG-3′); Gal-1 sh2 (5′-CCGGCCAGC
CTGGAAGTGTTGCAGACTCGAGTCTGCAACACTT
CCAGGCTGGTTTTTG-3′); Gal-1 sh3 (5′-CCGGGCT
GCCAGATGGATACGAATTCTCGAGAATTCGTATCC
ATCTGGCAGCTTTTTG -3′). GV248 and GV358 lenti-
viral vectors were constructed to silence and upregulate
the expression of LGALS1; a negative control vector con-
taining the cytomegalovirus (CMV) promoter and express-
ing high levels of green fluorescent protein (GFP) was also
created. The negative control was made from GV248 and
GV358 too. The lentiviral vectors were transfected into
MGC-803 cells at a multiplicity of infection (MOI) ranging
from 1 to 100 in the presence of 5 μg/ml polybrene
(Sigma-Aldrich, St. Louis, MO, USA). To produce stably
transfected cell lines, the cells were cultured in the pres-
ence of puromycin (Sigma-Aldrich). The cells were used
for subsequent experiments after the expression of the
target gene was confirmed using Western blot. After viral
infection, the groups were as follows: Gal-1-downregulated
CAFs (Down), and gal-1 overexpression CAFs (Over). And
Table 1 Association of Gal-1 and Gli1 with clinicopathological indicators
Parameter n Gal-1 Gli1
High Low P-value High Low P-value
Tumor size
< 5 cm 62 30 32 0.118 27 35 0.039
≥ 5 cm 49 31 18 31 18
Depth of tumor invasion
T1-T2 31 9 22 0.001 8 23 0.001
T3-T4 80 52 28 50 30
Histologic type
Well and moderately differentiated 70 39 31 0.834 37 33 0.868
Poorly and undifferentiated 41 22 19 21 20
TNM stage
I- II 30 10 20 0.005 9 21 0.004
III- IV 81 51 30 49 32
Lymph Nodes Metastasis
No 43 18 25 0.027 15 28 0.004
Yes 68 43 25 43 25
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Conditioned medium (CM) from NGFs (CM-NGFs),
CAFs(CM-CAFs), Over(CM-Over), Down (CM-Down)
was obtained by 48 h serum-starved cells, clarified by cen-
trifugation and used freshly.
Western blot analyses
Total lysates of treated cells were prepared using RIPA
buffer containing 1× Tris-buffered saline, 1 % Nonidet
P-40, 0.5 % sodium deoxycholate and 0.1 % sodium do-
decyl sulfate. Total proteins (50 μg) from each lysate
were separated by SDS/PAGE and transferred onto
PVDF membranes, and then probed with the indicated
antibodies using standard protocols.
RNA extraction and real-time PCR
Real-time PCR was performed to determine the mRNA
expression levels of LGALS1, SMO, Gli1, E-cadherin and
vimentin. Total RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instruction. First-strand reverse transcription was
performed using the PrimeScript RT reagent Kit (TaKaRa,
Dalian, China). The real-time PCR analyses were con-
ducted on an iQ5 Multicolor Real-Time PCR Detection
System (Bio-Rad, Hercules, CA, USA) using SYBR Green
Real-time PCR Master Mix (TaKaRa). The PCR program
was 30 s at 95 °C followed by 40 cycles at 95 °C for 5 s,
60 °C for 30 s and 72 °C for 30 s. Glyceraldehyde phos-
phate dehydrogenase (GAPDH) was used as the reference
control. Fold changes in the mRNA levels of target genes
were calculated relative to GAPDH. All results are re-
ported as the average ratios of three different independent
experiments. The following primers were used: Gal-1 (for-
ward): CTGGAAGTGTTGCAGAGGTGT and (reverse)
CTGGCTGATTTCAGTCAAAGG; β1-integrin (forward):
TGATTGGCTGGAGGAATGTTA and (reverse) GTTTC
TGGACAAGGTGAGCAA; SHH (forward): GACTCAG
AGGTGTAAGGACAAGTT and (reverse) CTCGGTCAC
CCGCAGTTT; SMO (forward) CAGGTGGATGGGGAC
TCTGTGAGT and (reverse) GAGTCATGACTCCTCGG
ATGAGG); Gli1 (forward) GGGATGATCCCACATCCT
CAGTC and (reverse) CTGGAGCAGCCCCCCCAGT;
N-cadherin (forward) GGCAGAAGAGAGACTGGGTC
and (reverse): GAGGCTGGTCAGCTCCTGGC; E-
cadherin (forward) TCGTCACCACAAATCCAGTG and
(5everse): CATTCACATCAAGCACATCC); vimentin (for-
ward) TGAATACCAAGACCTGCTCAA) and (reverse)
ATCAACCAGAGGGAGTGAATC); snali (forward) CAC
TGCCACAGGCCGTATC and (reverse): CTTGCCGCA
CACCTTACAG; MMP-9 (forward) TGGGGGGCAACT
CGGC and (reverse): GGAATGATCTCTAAGCCCAG;
and GAPDH (forward) TGACTTCAACAGCGACACCCA)
and (reverse) CACCCTGTTGCTGTAGCCAAA.
Quantification of Galectin-1 using Enzyme Linked Im-
munosorbent Assay (ELISA)
NGFs, CAFs, Over and Down culture supernatants were
harvested and stored at −80 °C. The level of Gal-1 was de-
termined using a commercial ELISA kit (Boster, Wuhan,
China). The ELISA detection sensitivities was ≥156 pg/mL
for Gal-1.
Proliferation assay
The Cell Counting Kit-8 (CCK-8) assay was used as a
qualitative index of cell proliferation. Ten thousand
cells were plated in 96-well microplates and cell counts
performed using a CCK-8 assay (Dojindo, Beijing, China),
according to the manufacturer’s protocol. Briefly, 10 μL
of CCK-8 solution was added to each well, and the
samples were incubated for 1 h before the absorbance
was measured at 450 nm. Experiments were performed
in triplicate.
Wound-healing assay
The cells were grown to 80-90 % confluence in a 6-well
plate, and a wound was created using a plastic pipette
tip across the cell surface. The remaining cells were
washed three times to remove cellular debris and incu-
bated at 37 °C with serum-free medium, CM-NGFs,
CM-CAFs, CM-Over, and CM-Down containing 10 μg/
mL mitomycin C (to block proliferation). The wounded
area was photographed at 0 h and 48 h time points. All
experiments were performed in triplicate.
Matrigel invasion assay
GC cell invasion was assessed using a chamber-based
invasion assay. In brief, the upper surface of the 24-well
transwell pates (pore size, 8.0 μm; Corning, New York,
USA) was coated with 150 mg Matrigel basement mem-
brane (BD Biosciences, San Diego, CA, USA). Cells were
cultured in serum-free RPMI 1640 medium overnight
then the cells centrifuged at 1,000 rpm for 5 min. The
cells were re-suspended in serum-free RPMI 1640
medium (st), CM-NGFs, CM-CAFs, CM-Over, or CM-
Down, then cell suspensions (200 μl containing 10,000
cells) were seeded onto the filters in 24-well chambers;
500 μl of complete growth was placed in the lower
chambers as a chemoattractant. The cells were allowed
to migrate for 18 h at 37 °C. Cells remaining on the
upper surface of the membrane were removed using a
cotton swab. The filters were fixed with 4 % parafor-
maldehyde, and the cells were stained with 0.05 % crys-
tal violet solution. The cells that had migrated from the
upper to the lower side of the filter were counted under
a light microscope in 10 randomly-selected fields at
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100× magnification. Tumor cell invasion assays were
performed in triplicate.
Transfection of siRNA
The siRNA against Gli1, β1-integrin and a negative control
siRNA were purchased from Genechem (Shanghai, China).
MGC-803 cells seeded in six-well plates were transfected
with control or Gli1 siRNA using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. The cells were harvested for further
experiments at 24 h after transfection.
Immunofluorescence microscopy
Prior to immunofluorescence analysis, cells were fixed
for 30 min with 4 % paraformaldehyde and perme-
abilized with 0.2 % Triton-X-100 for 10 min. The cover-
slips were incubated with primary antibodies at 1:100
dilutions overnight at 4 °C in a humidified chamber.
Following incubation phosphate-buffered solution (PBS)
washing steps, the appropriate Alexa Fluor 488-linked
secondary antibody (Cell Signaling Technology, Danvers,
MA, USA) was applied for 2 h at room temperature. The
cells were then rinsed with PBS, counterstained with 4′,6-
diamidino-2-phenylindole (DAPI), and images were taken
on a fluorescence microscope.
Statistical analyses
Protein expression levels and clinicopathological fea-
tures were compared using the λ2-test. Other data is
presented as the mean ± standard error values. Kaplan–
Meier survival curve was used to analyze patients’ over-
all survival rates, and the differences were compared
using the Log-rank test. The correlation was analyzed
using Spearman’s test. One-way ANOVA with the Least
Significant Difference (LSD) post hoc test was used for
multiple comparisons using SPSS version 13.0 software
(SPSS, Chicago, USA). P-values < 0.05 were considered
significant.
Results
CAF-derived Gal-1 induces EMT in GC cells via activation
of the Hh pathway
A previous study from our group described the isolation
of CAFs and normal gastric fibroblasts (NGFs), and the
preparation of recombinant lentiviruses to downregulate
Gal-1 expression in CAFs (Down) or overexpress Gal-1
in CAFs (Over) [6]. In the current study, we confirmed
that Over cells produced a much larger amount of Gal-1
protein than NGFs (Fig. 1a). Moreover, we confirmed
that Gal-1 was strongly expressed in fibroblasts in the



































































































Fig. 1 Expression of Gal-1 in CAFs and expression of Gli1 in human GC cells. a Western blot showing the expression of Gal-1 in NGFs, CAFs, Over
cells, Down cells and their respective conditioned medium (CM). b Quantification of Gal-1 expression relative to β-actin. *P < 0.05 vs. NGFs, **P < 0.01
vs. NGFs. c Expression of Gal-1 in supernatants was quantified using ELISA. Gal-1 showed increased expression in supernatant from Over cells and
reduced expression in supernatant from Down cells. d The expression of Gli1 at the protein level in the GC cell lines was determined by western
blotting. e qRT-PCR analysis of the GC cell lines revealed high levels of Gli1 mRNA in all tested cell lines. Expression levels relative to MGC-803
cells are shown. The expression of each target gene was normalized to the reference gene GAPDH. The bars represent the mean of three
independent experiments ± SD
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(Fig. 1a and b). To explore the secretion of Gal-1, the
concentration of Gal-1 in the supernatants was quanti-
fied by ELISA. Over cells secreted a larger quantity of
Gal-1 than CAFs, while NGFs and Down cells did not
secrete detectable levels of Gal-1 (Fig. 1c). Gli1 plays a
key role in the Hh signaling pathway. We examined the
expression of Gli1 in the GC cell lines MGC-803, AGS,
MNK-45, MKN-28, SGC-7901 and BGC-823 to identify
a cell line for our studies that expressed high levels of
Gli1. MGC-803 cells showed the highest level of Gli1
protein and mRNA expression (Fig. 1d and e), and was
selected for further in vitro studies.
Interactions between activated fibroblasts in the tumor
stroma and tumor cells increase the invasiveness of
cancer cells through reducing cell-cell contacts, inducing
EMT and promoting metastatic spread [23]. To explore
the role of Gal-1 in GC cells, we assessed the expression
of E-cadherin in MGC-803 cells following treatment
with conditioned media (CM) from NGFs (CM-NGFs),
CAFs (CM-CAFs), Over cells (CM-Over) or Down cells
(CM-Down). Compared to untreated MGC-803 cells, we
found that treatment of MGC-803 cells with CM-Over
significantly decreased E-cadherin expression and in-
creased vimentin and Gli1 expression (Fig. 2a). MGC-803
cells were treated with serum free medium, CM-NGFs,
CM-CAFs or CM-Down for 48 h. We observed that the
proliferation of MGC-803 cells was increased with
elevated Gal-1 expression (Fig. 2b). As shown in Fig. 2c
and d, MGC-803 cells exhibited significantly enhanced
migration and invasion capacity following treatment
with CM-Over compared with cells treated with serum
free medium, CM-NGFs, CM-CAFs and CM-Down.
Although Gal-1 influenced expression of E-cadherin,
the mechanisms through which the process occurs re-
main unclear. The Hh pathway guides cellular prolifera-
tion and differentiation in developmental pathways, so
its potential for inducing EMT is unsurprising [24].
Consequently, we hypothesized that Gal-1 induces EMT
via activation of the Hh signaling pathway. We observed
that GC cells exposed to Gal-1 exhibited enhanced migra-
tory and invasive potentials and underwent EMT. To
understand the influence of Gal-1 activation on the Hh
signaling pathway, we investigated the expression of Gli1
in MGC-803 cells. To our surprise, there was a substantial
increase in Gli1 expression at the levels of mRNA and
protein when MGC-803 cells were treated with CM-Over
(Fig. 3a).
To assess whether the activation of the Hh target gene
Gli1 is involved in Gal-1-induced EMT in GC cells, we
knocked down Gli1 expression in MGC-803 cells using
Gli1 siRNA (Fig. 3b). A wound-healing assay (Fig. 3c),
used to measure migration, demonstrated moderate
wound closure in Gli1 knockdown cells in the presence of
CM-Down compared with other conditions. In addition, a
cell invasion assay revealed that the enhanced invasiveness
of MGC-803 cells in the presence of CM-Over was abol-
ished by Gli1 knockdown and the number of migratory
cells reduced by 50 % compared with control siRNA-
treated cells (Fig. 3d). As shown in Fig. 3e, the reduced
expression of the epithelial marker E-cadherin in re-
sponse to CM-Over treatment was partially reversed
with Gli1 knockdown. Gal-1-induced expression of
snail and the mesenchymal markers N-cadherin and
vimentin was greatly reduced compared with cells
transfected with control siRNA. These results indicate
that Gal-1-induced invasion and EMT of the human
GC cells is mediated, at least in part, by Gli1. Consist-
ent with the inhibition of EMT, Gal-1-induced up-
regulation of the invasion-related protein MMP-9 was
partially abolished by Gli1 knockdown in GC cells
(Fig. 3e). These data suggest that activation of the Hh
pathway plays a pivotal role in Gal-1-induced GC cells
invasion and EMT.
Activation of the Gal-1/β1 integrin axis induces the ex-
pression of Gli1
Integrins in the extracellular matrix (ECM), including β1
integrin, bind with extracellular Gal-1 [9, 20–22, 25, 26].
Integrins appear to play important roles during pregnancy
through their involvement in cell invasion, migration and
EMT [27]. Previous studies revealed that extracellular
Gal-1 secreted by CAFs enhanced the invasiveness of GC
cells by upregulating the expression of β1 integrin [22].
Similarly, higher expression of β1 integrin was also shown
to induce EMT through the aberrant activation of the Hh
pathway [28]. Therefore, we speculated that Gal-1 could
activate the Hh pathway via binding to β1 integrin.
To confirm whether binding of Gal-1 to β1 integrin pro-
moted activation of the Hh signaling pathway, we knocked
down β1 integrin in MGC-803 cells using siRNA (Fig. 4a).
We examined the expression of EMT-related molecules in
control and Gal-1-stimulated MGC-803 cells using west-
ern blotting to measure protein levels and qRT-PCR to
measure RNA levels. As shown in Fig. 4b, the expression
of E-cadherin was significantly reduced in MGC-803 cells
after treated with CM-Over at both protein and mRNA
levels (P < 0.05). The protein and mRNA expression of
N-cadherin, vimentin, and snail were increased dramat-
ically. In contrast, there were no obvious increases in
the expression of N-cadherin or vimentin in MGC-803
cells exposed to Gal-1 when β1 integrin was knocked
down. The expression of E-cadherin in MGC-803 cells
was unaffected compared with control cells cultured in the
absence of CM-Over. Up-regulation of Gli1 expression in
response to CM-Over was abolished when β1 integrin was
knocked down in MGC-803 cells, while the expression of
SHH and SMO remained unchanged (Fig. 4b). These
results were also confirmed by immunocytochemistry
















































































































































































Fig. 2 Gal-1 expression affects EMT in GC cells. a CM from NGFs (CM-NGFs), CAFs (CM-CAFs), Over cells (CM-Over) and Down cells (CM-Down)
was harvested. MGC-803 cells were then treated with serum-free medium (st) or designated CM for 72 h, and the expression of E-cadherin,
vimentin and Gli1 monitored by western blot and qRT-PCR. b Gal-1 promotes the proliferation of MGC-803 cells. c Invasion assay. GC cells treated
with CM-Over exhibited significantly enhanced invasion abilities after 18 h in a scratch assay. Bars represent the mean number of invaded GC
cells (six fields/sample). *P < 0.05. d MGC-803 cells following treatment for 48 h with designated CM (original magnification × 100). *P < 0.05
when compared with st










































































































































































































































































































































Fig. 3 Downregulation of Gli1 abrogates Gal-1-induced migration, invasion and EMT of human GC cells. a The expression of Gli1 protein in MGC-803 cells
after treatment of Over-CM was evaluated by western blotting (left) and qRT-PCR (right). Gli1 expression was upregulated in a time dependent manner at
both the protein level and the mRNA level. * P< 0.05 when compared with expression at 0 h. b Silencing of Gli1 expression by siRNA at 48 h following
transfection was confirmed by western blotting (left) and qRT-PCR (right). *P< 0.05 when compared with the si-Control. c Gal-1-induced GC cell migratory
ability was impaired by Gli1 knockdown. Representative images of GC cells treated for 48 h with CM from Over cells and Down cells exhibited significantly
enhanced migratory abilities. These effects were abolished by Gli1 knockdown. *P< 0.05. d The effect of Gal-1 on cell invasion was impaired by Gli1
knockdown (original magnification × 100). *P< 0.05 when compared to control cells without treatment with Over-CM. e Loss of Gli1 expression reverses
the effects of Gal-1-induced EMT in GC cells. *P< 0.05. These results are presented as the mean ± SD of three independent experiments
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assays; MGC-803 cells showed markedly increased expres-
sion of Gli1 when grown in the presence of CM-Over,
while the increased expression was abolished by integrin
β1 knockdown (Fig. 4c). These findings suggest that β1 in-
tegrin activation is essential for the Gal-1-induced activa-





Fig. 4 β1 integrin is necessary for Gal-1-induced effects in GC cell migration, invasion, and EMT. a The silencing of β1-integrin expression by siRNA at
48 h was confirmed using western blotting (left) and qRT-PCR (right). *P < 0.05 when compared with the si-Control. b The expression of EMT-related
molecules (E-cadherin, N-cadherin, vimentin, and snail), invasion-related molecules (MMP-9), key molecules in the Hh pathway (SHH, SMO, and Gli1)
and β1 integrin were analyzed by western blotting (left). The mRNA expression levels were determined by qRT-PCR (right). *P < 0.05. The results are
presented as the mean ± SD of three independent experiments. c MGC-803 cells were labelled with fluorescein-conjugated Gli1 specific
antibody (green) following treatment with CM from Over (magnification × 200). The nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI). d The invasion-promoting effects of Gal-1 were abolished by Gli1 knockdown. The number of invading cells was quantified under a
light microscope by counting six random fields at a magnification of 200×. *P < 0.05. The data represent the results of three independent experiments
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expected, following treatment with CM-Over, MGC-803
cells exhibited enhanced invasive abilities compared with
untreated cells (Fig. 4d). MGC-803 cells with β1 integrin
knockdown exhibited impaired invasive abilities even
when they were exposed to higher expression of Gal-1.
Taken together, these data indicate that Gal-1 can induce
EMT through stimulating Gli1 expression in GC cells, a
process that is mediated by β1 integrin, a receptor of Gal-1.
Correlation between Gal-1 and Gli1 expression, and
clinicopathological features
We performed immunohistochemical analysis to evaluate
the clinical significance of Gal-1 and Gli1 expression in 111
GC tissue samples. Gal-1 showed significantly higher
expression in 54.95 % (61/111) of GC tissues compared to
adjacent normal tissues (Fig. 5a–c). Likewise, Gli1 expres-
sion was detected in 52.25 % (58/111) of GC tissues,
indicating that Gli1 expression was higher than in adjacent
normal tissues (Fig. 5d–f). Moderate Gal-1 staining was
detected in the stroma of normal mucosa, while the Gal-1
staining intensity was significantly higher in the stroma and
epithelium of the GC tissues. Gli1 staining was predomin-
antly observed in the cell cytoplasm and nucleus.
Spearman’s correlation analysis indicated a positive associ-
ation between Gal-1 and Gli1 expression in GC tissues
































Fig. 5 Immunohistochemical staining of Gal-1 and Gli1 in GC sections. Expression of Gal-1 is low in normal tissues (a), while staining ranges from
weak (b) to strong (c) in GC tissues. Likewise, Gli1 shows low expression in normal tissues (d), while expression ranges from low to high in GC
tissues. Western blot analysis of Gal-1 and Gli1 expression in GC tissues showing that expression is significantly correlated with lymph node
metastasis (g), the depth of tumor invasion (h), and TNM stage (i)
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As shown in Table 1, Gal-1 expression was highly asso-
ciated with the depth of tumor invasion (P = 0.001), lymph
node metastasis (P = 0.027), and TNM stage (P = 0.005).
Meanwhile, Gli1 expression was significantly associated
with tumor size (P = 0.039), the depth of tumor invasion
(P = 0.001), lymph node metastasis (P = 0.004), and TNM
stage (P = 0.004). Figure 5g-i, which shows western blots
of GC tissues, confirmed the positive correlation between
Gal-1 and Gli1 expression.
Both Gal-1 and Gli1 expression are associated with a poor
prognosis in GC patients
As shown in Fig. 6a and b, patients were divided into
low and high expression groups based on IHC scores.
Kaplan–Meier curves and the log-rank test were used to
assess the prognostic value of Gal-1 and Gli1 in gastric
tumors. The results showed a significant difference in
overall survival probability between groups of patients
with high expression of Gal-1 and Gli1 and those with
low expression of Gal-1 and Gli1. Statistical analyses
demonstrated that high Gal-1 and Gli1 expression was
associated with poor overall survival (P = 0.000 and P =
0.000, respectively). Furthermore, in univariate analysis,
patients with high expression of Gal-1 and Gli1 had a
markedly higher risk of death [HR 0.036 (0.010–0.135),
P < 0.001; 5.239 (1.554–17.668), P < 0.01, respectively,
Table 2]. In addition, the remaining indicators, including
the depth of tumor invasion, lymph node metastasis and
TNM stage, were also significantly correlated with overall
survival based on univariate analysis (Table 2). However,
as show in Table 2, age, gender, size and differentiation
status had no prognostic value. The multivariate analysis
further demonstrated that the expression of Gal-1 and
Gli1 were independent prognostic factors for GC patients
(P = 0.000 and P = 0.002, respectively; Table 2).
Discussion
The stroma reaction involves secreted factors from
both host and tumor cells that function to promote the
desmoplastic response and accelerate the progression
of GC, highlighting the complex interplay between can-
cer cells and the stroma involved in the induction of
EMT [29]. Migration and invasion are two basic fea-
tures of malignant tumor cells. EMT is an important
mechanism in tumor invasion and metastasis in which












Fig. 6 Prognostic significance of Gal-1 and Gli1 expression in GC patients. Kaplan–Meier analysis of overall survival based on Gal-1 (a) Gli1
(b) expression in 111 patients. Kaplan–Meier survival curves show that high Gal-1 and Gli1 expression is associated with poor overall survival
Table 2 Univariate and multivariate analysis of prognostic indicators in gastric cancer patients
Indicator Univariate analysis Multivariate analysis
HR (95 % CI) P-value HR (95 % CI) P–value
Age (<60/≥ 60) 0.691 (0.373–1.279) 0.239 NA NA
Gender (male/female) 1.070 (0.586–1.954) 0.826 NA NA
Tumor size (<5 cm /≥ 5 cm) 1.812 (0.945–3.476) 0.074 NA NA
Depth of tumor invasion (T3-T4/T1-T2) 8.285 (1.229–55.866) 0.030 6.481 (1.108–37.907) 0.038
Histologic type (well, moderate/poor, undifferentiated) 1.168 (0.646–2.114) 0.607 NA NA
TNM stage (III- IV /I- II) 0.083 (0.011–0.624) 0.016 0.142 (0.023–0.865) 0.034
Lymph Nodes Metastasis (yes/no) 0.131 (0.044–0.395) 0.000 0.162 (0.058–0.455) 0.001
Gal-1 (+ ~ +++/−) 0.036 (0.010–0.135) 0.000 0.035 (0.009–0.128) 0.000
Gli1 (+ ~ +++/−) 5.239 (1.554–17.668) 0.008 6.401 (1.958–20.928) 0.002
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12]. Gal-1 was reported to induce EMT in hepatocellular
carcinoma [11], but no data on GC has been provided to-
date. Therefore, we analyzed the connection between Gal-
1 and EMT in GC. Our present work demonstrates that
Gal-1 secreted by CAFs could play a role in the progres-
sion of GC. Elevation of Gal-1 levels in the tumor micro-
environment promoted the transition from epithelial cell
morphology to the fibroblastoid phenotype, loss of the
adherens junction protein E-cadherin and an increase of
the mesenchymal marker vimentin.
As one of the most important signaling pathways, Hh
is involved in the regulation of GC cell proliferation,
migration, invasion, stem cell maintenance, and lym-
phangiogenesis [30]. Gli1 has been identified as the
final transcriptional effector and the key marker of the
Hh signaling pathway, and has been shown to be acti-
vated in various human malignancies such as prostate
cancer and gastrointestinal cancer [30, 31]. Addition-
ally, a previous study showed that, in GC, the levels of the
Hh pathway marker Gli1 were associated with levels of
the EMT markers E-cadherin and snail [32]. Interestingly,
a recent study by Wang et al. suggested that Gal-1 is
required for Hh signaling pathway activation in pancre-
atic cancer [33]. In our study, to determine the mech-
anism of Gal-1-regulated EMT in GC, we modified
Gal-1 expression levels and examined the effects on
Gli1 expression. As anticipated, increasing the expres-
sion of Gal-1 resulted in upregulation of Gli1, further
demonstrating the positive association between Gal-1
and Gli1 in GC. Examination of the protein expression
levels of EMT markers, as well as migration and invasion
assays showed that knock down of Gli1 in MGC-803 cells
abolished the effects of Gal-1 in promoting EMT, suggest-
ing that Gli1 plays an important role in Gal-1-induced
EMT in GC. Gal-1 may have a variety of roles in tumor
metastasis, and our research clearly showed that Gli1 is
involved in the promotion of EMT-induced metastasis by
Gal-1. We further revealed that overexpression of Gal-1 in
CAFs induced cancer cells to achieve a more malignant
phenotype through a non-classical Hh signaling pathway.
However, the correlation between Gal-1 and Gli1 in GC
and their clinicopathological significance has not been re-
ported in the literature. This is the first report revealing a
positive relationship between Gal-1 expression and the
levels of Gli1, an important member of Hh signaling path-
way in vivo, suggesting that the interaction of Gal-1
and the Hh signaling pathway may be implicated in pri-
mary GC tumorigenesis, progression, and metastasis.
Furthermore, most studies confirm that high Gal-1
[10] and Gli1 [32] expression is significantly associated
with worse clinicopathological parameters and de-
creased overall survival in GC.
Gal-1 is a secreted protein present in the extracellular
matrix [34]. Regardless of whether or not the signal
peptide is present in the primary polypeptide sequence,
Gal-1 exists as a non-covalent homodimer in its se-
creted form [34]. Moiseeva et al. demonstrated that
Gal-1 directly binds to β1 integrin but not to the α sub-
units on the cell surface, enhances activation of β1 in-
tegrin, and regulates multiple tumor-promoting functions
[21]. Gal-1 binds to lactosamine sequences [20]. The
membrane receptor-type protein β1 integrin contains the
lactosamine sequence in its extracellular domain [20]. He
et al. have shown that Gal-1 in CAFs promote the inva-
siveness of GC cells by direct binding to β1 integrin on
the cell surface [22]. Additionally, their work has revealed
a positive correlation between Gal-1 and β1 integrin ex-
pression in GC [22]. In addition, the downregulation
of β1 integrin reduces the expression of Gli1 in human
prostate prostate cancer cells [35]. Our study found
that GC cells exhibited enhanced invasion as well as
up-regulation of Gli1 in response to CM from Over
cells. These effects were abolished by β1 integrin
knockdown. Furthermore, the ability of Gal-1 to stimu-
late EMT was reversed by knockdown of β1 integrin.
These findings suggest that β1 integrin activates the
Hh pathway, resulting in the triggering of Gal-1-
mediated EMT in GC.
Conclusions
Our present results, combined with preliminary findings
from other groups, have provided evidence that high ex-
pression of Gal-1 in GC tissues contributes tumor cells
migration and invasion via Gli1-driven EMT after bind-
ing of Gal-1 to β1 integrin. These findings not only im-
prove our understanding of the molecular mechanisms
underlying the effects of Gal-1 in GC metastasis, but
also provide new insight into Gal-1 as an important
therapeutic target associated with GC metastasis.
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